Kushnir Yu. A., Shevchenko-Bitensky K. V.

DYNAMICS OF CLINICAL AND PSYCHOPATHOLOGICAL STRUCTURE AND SEVERITY OF NEGATIVE SYMPTOMS IN PATIENTS WITH SCHIZOPHRENIA

---

Show/Download

About the author:

Kushnir Yu. A., Shevchenko-Bitensky K. V.

Heading:

CLINICAL AND EXPERIMENTAL MEDICINE

Type of article:

Scientific article

Annotation:

The article is devoted to the negative symptoms of schizophrenia, which have the most significant impact on the social functioning of patients. The study involved 252 patients with negative symptoms of schizophrenia: 83 patients with first-episode schizophrenia, 88 patients with schizophrenia in acute exacerbation, and 81 patients with schizophrenia in remission. The study used an integrated approach consisting of clinical and psychopathological, psychometric (PANSS scale) and statistical research methods. The clinical and psychopathological features of the structure and severity of negative symptoms in patients with schizophrenia at different stages of the disease were established. In patients with the first episode of schizophrenia, negative symptoms were fragmented and affected the emotional, social and volitional spheres, which was manifested by emotional alienation, avoidance of communication and apathetic detachment. In patients with schizophrenia in the state of exacerbation, negative symptoms acquired moderate values: symptoms of affective flattening, impaired abstract thinking and increased stereotypy, as well as impaired fluency of speech. In patients with schizophrenia in remission, negative symptoms were leading in all characteristics. Of particular importance were disorders of the emotional and social spheres: emotional alienation, blunted affect, and poor sociability, which were the leading negative symptoms. The data obtained can be used to establish diagnostic criteria among patients with negative symptoms of schizophrenia, depending on the dynamics of the disease.

Tags:

Bibliography:

1. World Health Organization. World report on ageing and health. Geneva: WHO; 2015. 260 p. Available from: http://apps.who.int/iris/bitstream/handle/ 10665/186463/9789240694811_eng.pdf?sequence=1.
2. Bucci P, Galderisi S. Categorizing and assessing negative symptoms. Current opinion in psychiatry. 2017;30(3):201-208. DOI: https://doi. org/10.1097/ YCO.0000000000000322.
3. Jaeschke K. Global estimates of service coverage for severe mental disorders: findings from the WHO Mental Health Atlas 2017. Glob Ment Health. 2021;8:e27.
4. Kushnir YuA. Psykhopatolohichna kharakterystyka nehatyvnykh i pozytyvnykh symptomiv pry shyzofreniyi. Perspektyvy ta innovatsiyi nauky. 2023;15(33):1148-1159. DOI: https://doi.org/10.52058/2786-4952-2023-15(33)-1148-1159. [in Ukrainian].
5. Fleischhacker W. The efficacy of cariprazine in negative symptoms of schizophrenia: Post hoc analyses of PANSS individual items and PANSS-derived factors. Eur. Psychiatry. 2019;58:1-9.
6. An der Heiden W, Leber A, Häfner H. Negative symptoms and their association with depressive symptoms in the long-term course of schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2016;266:387-396. DOI: https://doi.org/10.1007/s00406-016-0697-2.
7. Fleischhacker W, Galderisi S, Laszlovszky I, Szatmári B, Barabássy Á, Acsai K, et al. The efficacy of cariprazine in negative symptoms of schizophrenia: Post hoc analyses of PANSS individual items and PANSS-derived factors. Eur Psychiatry. 2019;58:1-9. DOI: 10.1016/j. eurpsy.2019.01.015.
8. Almulla AF, Al-Hakeim HK, Maes M. Schizophrenia phenomenology revisited: positive and negative symptoms are strongly related reflective manifestations of an underlying single trait indicating overall severity of schizophrenia. CNS spectrums. 2021;26(4):368-377. DOI: https://doi.org/10. 1017/S1092852920001182.
9. Edgar CJ, Blaettler T, Bugarski-Kirola D, Le Scouiller S, Garibaldi GM, Marder SR. Reliability, validity and ability to detect change of the PANSS negative symptom factor score in outpatients with schizophrenia on select antipsychotics and with prominent negative or disorganized thought symptoms. Psychiatry Research. 2014;218(1-2):219-224. DOI: .
10. Galderisi S, Mucci A, Buchanan RW, Arango C. Negative symptoms of schizophrenia: new developments and unanswered research questions. Lancet Psychiatry. 2018;5(8):664-677. DOI: 10.1016/S2215-0366(18)30050-6.
11. Institute of health Metrics and Evaluation (IHME). Global Health Data Exchange (GHDx). Seattle: IHME; 2021. Available from: .
12. Hansbauer M, Wobrock T, Kunze B, Langguth B, Landgrebe M, Eichhammer P, et al. Efficacy of high-frequency repetitive transcranial magnetic stimulation on PANSS factors in schizophrenia with predominant negative symptoms – Results from an exploratory re-analysis. Psychiatry. 2018;263:22-29. DOI: https://doi.org/10.1016/j.psychres.2018.02.030.
13. Sabe M, Kirschner M, Kaiser S. Prodopaminergic Drugs for Treating the Negative Symptoms of Schizophrenia: Systematic Review and Meta-analysis of Randomized Controlled Trials. Journal of Clinical Psychopharmacology. 2019;39(6):658-664. DOI: https://doi.org/10.1097/ JCP.0000000000001124.
14. Capatina OO, Miclutia IV. Are negative symptoms in schizophrenia a distinct therapeutic target? Clujul Med. 2018;91(1):58-64. DOI: 10.15386/cjmed-864.

Publication of the article:

«Bulletin of problems biology and medicine», 2025 Issue 1, 176, 227-238 pages, index UDC 616.895.8

DOI:

10.29254/2077-4214-2025-1-176-227-238